ADMA Stock Gains 17% in Three Months: Buy, Sell or Hold?

ADMA Biologics (ADMA) has been a consistent market outperformer in recent times. Shares have gained 17.2% in the past three months against the industry’s decline of 10.6%. The stock has also outperformed the sector and the S&P 500 in this timeframe.ADMA Outperforms Industry, Sector & S&P 500Image Source: Zacks Investment ResearchADMA Biologics markets plasma-derived biologics for the treatment of immune deficiencies and the prevention of certain infectious diseases.Though the first-quarter results (reported ...